Page last updated: 2024-08-21

dihydroergotamine and erythromycin

dihydroergotamine has been researched along with erythromycin in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19903 (30.00)18.7374
1990's0 (0.00)18.2507
2000's3 (30.00)29.6817
2010's4 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dantzig, AH; Ekins, S; Kim, RB; Lan, LB; Leake, BF; Schuetz, EG; Schuetz, JD; Shepard, RL; Wikel, JH; Winter, MA; Wrighton, SA; Yasuda, K1
Furuya, K; Lan, LB; Sanglard, D; Schuetz, EG; Schuetz, JD; Yasuda, K1
Pratim Roy, P; Roy, K1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Adnet, P; Asseman, P; Lacroix, D; Leroy, F; Pruvost, P; Thery, C1
Boucharlat, J; Carpentier, P; Charignon, Y; Denis, B; Franco, A; Hommel, M1
Guilhaume, B; Lesgourgues, B; Luton, JP; Neveux, E; Picard, J1

Reviews

1 review(s) available for dihydroergotamine and erythromycin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

9 other study(ies) available for dihydroergotamine and erythromycin

ArticleYear
Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
    Molecular pharmacology, 2002, Volume: 61, Issue:5

    Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Ergonovine; Fluoxetine; Humans; Models, Molecular; Oxytocics; Protein Conformation; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship; Swine; Transfection; Vinblastine

2002
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
    The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:1

    Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dihydroergocryptine; Drug Interactions; Enzyme Inhibitors; Fluconazole; Humans; Mice; Mice, Knockout; Microsomes, Liver; Oxidoreductases, N-Demethylating; Recombinant Proteins; Reserpine; Swine; Tissue Distribution; Transfection; Vinblastine

2002
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:7

    Topics: Algorithms; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Factor Analysis, Statistical; Least-Squares Analysis; Linear Models; Models, Molecular; Neural Networks, Computer; Quantitative Structure-Activity Relationship; Reproducibility of Results

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
    Journal of medicinal chemistry, 2013, Feb-14, Volume: 56, Issue:3

    Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs

2013
Dihydroergotamine-erythromycin-induced ergotism.
    Annals of internal medicine, 1988, Aug-01, Volume: 109, Issue:3

    Topics: Aged; Dihydroergotamine; Drug Interactions; Ergotism; Erythromycin; Humans; Male

1988
[Ergotism in a psychiatric setting caused by combined dihydroergotamine-erythromycin propionate. Apropos of a case].
    Annales medico-psychologiques, 1980, Volume: 138, Issue:3

    Topics: Adolescent; Dihydroergotamine; Ergotism; Erythromycin; Humans; Male; Mental Disorders

1980
[Acute ergotism caused by the interaction of erythromycin propionate and dihydroergotamine].
    La Nouvelle presse medicale, 1981, Sep-26, Volume: 10, Issue:34

    Topics: Acute Disease; Bipolar Disorder; Dihydroergotamine; Drug Synergism; Ergotism; Erythromycin; Humans; Male; Middle Aged

1981